Article(id=1329529185267200582, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329529184759689798, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2024.08.001, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1716912000000, receivedDateStr=2024-05-29, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794914059225, onlineDateStr=2026-11-17, pubDate=1723219200000, pubDateStr=2024-08-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794914059225, onlineIssueDateStr=2026-11-17, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794914059225, creator=13701087609, updateTime=1794914059225, updator=13701087609, issue=Issue{id=1329529184759689798, tenantId=1146029695717560320, journalId=1319690329412173987, year='2024', volume='45', issue='8', pageStart='803', pageEnd='902', issueExtLink='null', onlineDate='null', pubDate='1723219200000', pubDateStr='2024-08-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794914059104, creator='13701087609', updateTime=1794962181451, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1329731024885494053, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329529184759689798, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1329731024885494054, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329529184759689798, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=803, endPage=808, ext={EN=ArticleExt(id=1329529185481110087, articleId=1329529185267200582, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Advances in clinical application of immunotherapy for triple-negative breast cancer, columnId=1325221107665612978, journalTitle=World Clinical Drug, columnName=Topic, runingTitle=null, highlight=null, articleAbstract=

Triple-negative breast cancer (TNBC) is a subtype of breast cancer that is negative for estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2, and is significantly more aggressive and progressive than other subtypes. At present, the main treatment is surgery combined chemotherapy, but treatment efficacy of the advanced TNBC patients is poor. With the in-depth study of TNBC immune microenvironment, immunotherapy has shown potential therapeutic value. The immunotherapy of TNBC mainly includes immune checkpoint blockers, cell therapy, tumor vaccines and adjustment of tumor microenvironment. This article reviewed and summarized the current status and progress of immunotherapy, which contributed to the new understanding of TNBC immunotherapy.

, authors=Liang ZHANG1, 2, Yanqiang YANG1, 3, Zifang WU4, *, Jiuyang LIU1, *, authorsList=Liang ZHANG, Yanqiang YANG, Zifang WU, Jiuyang LIU, authorCompany=null, correspAuthors=Zifang WU, Jiuyang LIU, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329529185984426568, articleId=1329529185267200582, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=三阴性乳腺癌免疫治疗的临床应用进展, columnId=1325221107824996532, journalTitle=世界临床药物, columnName=医药专论, runingTitle=null, highlight=null, articleAbstract=

三阴性乳腺癌(triple-negative breast cancer,TNBC)是一种雌激素受体、孕激素受体和人类表皮生长因子受体2阴性的乳腺癌亚型,其侵袭性及疾病进展速度明显高于其他亚型。目前其主要治疗为手术联合化疗,但晚期TNBC患者的治疗效果不佳。随着对TNBC免疫微环境深入研究,免疫疗法已显示出潜在的治疗价值。TNBC免疫治疗主要包括免疫检查点阻断剂、细胞治疗、肿瘤疫苗以及调整肿瘤微环境。该文对免疫疗法的现状和进展作回顾及总结,有助于TNBC免疫治疗的新认识。

, authors=张亮1, 2, 杨彦强1, 3, 吴梓芳4, *, 刘九洋1, *, authorsList=张亮, 杨彦强, 吴梓芳, 刘九洋, authorCompany=null, correspAuthors=吴梓芳, 刘九洋, authorNote=

张亮,副主任医师,研究方向:乳腺癌诊疗与机制研究。

杨彦强,主治医师,研究方向:乳腺癌诊疗与机制研究。

, correspAuthorsNote=
吴梓芳,副主任技师,研究方向:超声影像与临床应用。
刘九洋,副主任医师,研究方向:乳腺癌的机制研究。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=Lw2nqD7pVOAMswyYCDIJ4g==, magXml=qEhTfwfZiS1zj20Rcuhq+A==, pdfUrl=null, pdf=P+EvSBAUSSTzKlIc6tY05Q==, pdfFileSize=1587645, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=kxV/Rzyl2kdmIsKbnBC8bQ==, mapNumber=null, fund=null)}, authors=[Author(id=1329529186575823446, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329529186651320921, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, authorId=1329529186575823446, language=EN, stringName=Liang ZHANG, firstName=Liang, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei Province, China
2.Department of Oncology, Urumqi Friendship Hospital, Urumqi 830049, Xinjiang Uygur Autonomous Region, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329529186768761434, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, authorId=1329529186575823446, language=CN, stringName=张亮, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.武汉大学中南医院甲状腺乳腺外科,湖北 武汉 430071
2.乌鲁木齐市友谊医院肿瘤科,新疆 乌鲁木齐 830049, bio={"content":"

张亮,副主任医师,研究方向:乳腺癌诊疗与机制研究。

"}, bioImg=null, bioContent=

张亮,副主任医师,研究方向:乳腺癌诊疗与机制研究。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329529186240279113, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, xref=1., ext=[AuthorCompanyExt(id=1329529186248667722, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, companyId=1329529186240279113, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei Province, China), AuthorCompanyExt(id=1329529186273833547, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, companyId=1329529186240279113, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.武汉大学中南医院甲状腺乳腺外科,湖北 武汉 430071)]), AuthorCompany(id=1329529186332553804, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, xref=2., ext=[AuthorCompanyExt(id=1329529186340942413, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, companyId=1329529186332553804, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Oncology, Urumqi Friendship Hospital, Urumqi 830049, Xinjiang Uygur Autonomous Region, China), AuthorCompanyExt(id=1329529186349331022, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, companyId=1329529186332553804, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.乌鲁木齐市友谊医院肿瘤科,新疆 乌鲁木齐 830049)])]), Author(id=1329529186861036124, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329529186965893727, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, authorId=1329529186861036124, language=EN, stringName=Yanqiang YANG, firstName=Yanqiang, middleName=null, lastName=YANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 3, address=1.Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei Province, China
3.Department of General Surgery, People's Hospital of Gannan Tibetan Autonomous Prefecture of Gansu Province, Gannan 747000, Gansu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329529188605866592, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, authorId=1329529186861036124, language=CN, stringName=杨彦强, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 3, address=1.武汉大学中南医院甲状腺乳腺外科,湖北 武汉 430071
3.甘肃省甘南藏族自治州人民医院普外一科,甘肃 甘南 747000, bio={"content":"

杨彦强,主治医师,研究方向:乳腺癌诊疗与机制研究。

"}, bioImg=null, bioContent=

杨彦强,主治医师,研究方向:乳腺癌诊疗与机制研究。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329529186240279113, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, xref=1., ext=[AuthorCompanyExt(id=1329529186248667722, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, companyId=1329529186240279113, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei Province, China), AuthorCompanyExt(id=1329529186273833547, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, companyId=1329529186240279113, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.武汉大学中南医院甲状腺乳腺外科,湖北 武汉 430071)]), AuthorCompany(id=1329529186416439887, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, xref=3., ext=[AuthorCompanyExt(id=1329529186424828496, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, companyId=1329529186416439887, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Department of General Surgery, People's Hospital of Gannan Tibetan Autonomous Prefecture of Gansu Province, Gannan 747000, Gansu Province, China), AuthorCompanyExt(id=1329529186433217105, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, companyId=1329529186416439887, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.甘肃省甘南藏族自治州人民医院普外一科,甘肃 甘南 747000)])]), Author(id=1329529188748472930, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329529188861719140, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, authorId=1329529188748472930, language=EN, stringName=Zifang WU, firstName=Zifang, middleName=null, lastName=WU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=4, *, address=4.Department of Ultrasound Imaging, Wuhan University Hospital, Wuhan 430071, Hubei Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329529188962382437, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, authorId=1329529188748472930, language=CN, stringName=吴梓芳, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=4, *, address=4.武汉大学医院超声影像科,湖北 武汉 430071, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329529186491937362, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, xref=4., ext=[AuthorCompanyExt(id=1329529186500325971, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, companyId=1329529186491937362, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=4.Department of Ultrasound Imaging, Wuhan University Hospital, Wuhan 430071, Hubei Province, China), AuthorCompanyExt(id=1329529186508714580, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, companyId=1329529186491937362, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=4.武汉大学医院超声影像科,湖北 武汉 430071)])]), Author(id=1329529189084017255, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329529189289538153, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, authorId=1329529189084017255, language=EN, stringName=Jiuyang LIU, firstName=Jiuyang, middleName=null, lastName=LIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329529189411172970, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, authorId=1329529189084017255, language=CN, stringName=刘九洋, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.武汉大学中南医院甲状腺乳腺外科,湖北 武汉 430071, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329529186240279113, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, xref=1., ext=[AuthorCompanyExt(id=1329529186248667722, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, companyId=1329529186240279113, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei Province, China), AuthorCompanyExt(id=1329529186273833547, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, companyId=1329529186240279113, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.武汉大学中南医院甲状腺乳腺外科,湖北 武汉 430071)])])], keywords=[Keyword(id=1329529189604110955, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, language=EN, orderNo=1, keyword=triple-negative breast cancer), Keyword(id=1329529189721551468, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, language=EN, orderNo=2, keyword=immunotherapy), Keyword(id=1329529189935460973, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, language=EN, orderNo=3, keyword=tumor microenvironment), Keyword(id=1329529190036124270, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, language=CN, orderNo=1, keyword=三阴性乳腺癌), Keyword(id=1329529190216479343, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, language=CN, orderNo=2, keyword=免疫治疗), Keyword(id=1329529190329725552, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, language=CN, orderNo=3, keyword=肿瘤微环境。)], refs=[Reference(id=1329529190648492657, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249., articleTitle=null, refAbstract=null), Reference(id=1329529190753350258, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Denkert C, Liedtke C, Tutt A, et al. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies[J]. Lancet, 2017, 389(10087): 2430-2442., articleTitle=null, refAbstract=null), Reference(id=1329529190912733811, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving ratient selection for treatment[J]. Cancer Discov, 2019, 9(2): 176-198., articleTitle=null, refAbstract=null), Reference(id=1329529191042757236, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence[J]. Clin Cancer Res, 2007, 13(15 Pt 1): 4429-4434., articleTitle=null, refAbstract=null), Reference(id=1329529191193752182, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3 771 patients treated with neoadjuvant therapy[J]. Lancet Oncol, 2018, 19(1): 40-50., articleTitle=null, refAbstract=null), Reference(id=1329529191290221175, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Farshbafnadi M, Pastaki Khoshbin A, Rezaei N. Immune checkpoint inhibitors for triple-negative breast cancer: from immunological mechanisms to clinical evidence[J]. Int Immunopharmacol, 2021, 98: 107876., articleTitle=null, refAbstract=null), Reference(id=1329529191432827512, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase Ⅱ KEYNOTE-086 study[J]. Ann Oncol, 2019, 30(3): 397-404., articleTitle=null, refAbstract=null), Reference(id=1329529193030857337, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Winer EP, Lipatov O, Im SA, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2021, 22(4): 499-511., articleTitle=null, refAbstract=null), Reference(id=1329529193127326330, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Schmid P, Lipatov O, Im SA, et al. Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study[J]. Eur J Cancer, 2023, 195: 113393., articleTitle=null, refAbstract=null), Reference(id=1329529193223795323, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Emens LA, Adams S, Barrios CH, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis[J]. Ann Oncol, 2021, 32(8): 983-993., articleTitle=null, refAbstract=null), Reference(id=1329529193295098492, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial[J]. Lancet, 2020, 396(10265): 1817-1828., articleTitle=null, refAbstract=null), Reference(id=1329529193366401661, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Wang C, Liu Z, Chen X, et al. Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase Ⅱ trial[J]. Nat Commun, 2023, 14(1): 6654., articleTitle=null, refAbstract=null), Reference(id=1329529193437704830, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial[J]. Lancet, 2020, 396(10257): 1090-1100., articleTitle=null, refAbstract=null), Reference(id=1329529193550951039, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Park JW, Liu MC, Yee D, et al. Adaptive randomization of neratinib in early breast cancer[J]. N Engl J Med, 2016, 375(1): 11-22., articleTitle=null, refAbstract=null), Reference(id=1329529193618059904, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Loibl S, Untch M, Burchardi N, et al. A randomised phase Ⅱstudy investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study[J]. Ann Oncol, 2019, 30(8): 1279-1288., articleTitle=null, refAbstract=null), Reference(id=1329529193697751681, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer[J]. N Engl J Med, 2020, 382(9): 810-821., articleTitle=null, refAbstract=null), Reference(id=1329529193781637762, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Pusztai L, Denkert C, O'Shaughnessy J, et al. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522[J]. Ann Oncol, 2024, 35(5): 429-436., articleTitle=null, refAbstract=null), Reference(id=1329529193878106755, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)乳腺癌诊疗指南: 2023[M]. 北京: 人民卫生出版社, 2023., articleTitle=null, refAbstract=null), Reference(id=1329529193961992836, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Buchan SL. CTLA-4: checkpoints beyond the membrane[J]. Mol Ther, 2024, 32(2): 279-281., articleTitle=null, refAbstract=null), Reference(id=1329529194024907397, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy[J]. Blood, 2018, 131(1): 58-67., articleTitle=null, refAbstract=null), Reference(id=1329529194163319431, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Specht J, Lee S, Turtle C, et al. Abstract P2-09-13: A phase I study of adoptive immunotherapy for ROR1+ advanced triple negative breast cancer (TNBC) with defined subsets of autologous T cells expressing a ROR1-specific chimeric antigen receptor (ROR1-CAR)[J]. Cancer Res, 2019, 79(4_Supplement): P2-09-13., articleTitle=null, refAbstract=null), Reference(id=1329529194226233992, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Yang Y, Vedvyas Y, McCloskey JE, et al. Abstract 2322: ICAM-1 targeting CAR-T cell therapy for triple negative breast cancer[J]. Cancer Res, 2019, 79(13_Supplement): 2322., articleTitle=null, refAbstract=null), Reference(id=1329529194335285897, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Xia L, Zheng ZZ, Liu JY, et al. EGFR-targeted CAR-T cells are potent and specific in suppressing triple-negative breast cancer both in vitro and in vivo[J]. Clin Transl Immunology, 2020, 9(5): e01135., articleTitle=null, refAbstract=null), Reference(id=1329529194469503626, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Zhang L, Meng Y, Feng X, et al. CAR-NK cells for cancer immunotherapy: from bench to bedside[J]. Biomark Res, 2022, 10(1): 12., articleTitle=null, refAbstract=null), Reference(id=1329529194549195403, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Raftery MJ, Franzén AS, Radecke C, et al. Next generation CD44v6-specific CAR-NK cells effective against triple negative breast cancer[J]. Int J Mol Sci, 2023, 24(10): 9038., articleTitle=null, refAbstract=null), Reference(id=1329529194649858700, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Hu Z. Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer[J]. Sci Rep, 2020, 10(1): 2815., articleTitle=null, refAbstract=null), Reference(id=1329529194712773261, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=Zacharakis N, Huq LM, Seitter SJ, et al. Breast cancers are immunogenic: immunologic analyses and a phase Ⅱ pilot clinical trial using mutation-reactive autologous lymphocytes[J]. J Clin Oncol, 2022, 40(16): 1741-1754., articleTitle=null, refAbstract=null), Reference(id=1329529194796659342, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=Tay C, Tanaka A, Sakaguchi S. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy[J]. Cancer Cell, 2023, 41(3): 450-465., articleTitle=null, refAbstract=null), Reference(id=1329529194888934031, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=Hasegawa K, Ikeda Y, Kunugi Y, et al. Phase Ⅰ study of multiple epitope peptide vaccination in patients with recurrent or persistent cervical cancer[J]. J Immunother, 2018, 41(4): 201-207., articleTitle=null, refAbstract=null), Reference(id=1329529194977014416, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=Takeda K, Kitaura K, Suzuki R, et al. Quantitative T-cell repertoire analysis of peripheral blood mononuclear cells from lung cancer patients following long-term cancer peptide vaccination[J]. Cancer Immunol Immunother, 2018, 67(6): 949-964., articleTitle=null, refAbstract=null), Reference(id=1329529195073483409, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=Butterfield LH, Zhao F, Lee S, et al. Immune correlates of GM-CSF and melanoma peptide vaccination in a randomized trial for the adjuvant therapy of resected high-risk melanoma (E4697)[J]. Clin Cancer Res, 2017, 23(17): 5034-5043., articleTitle=null, refAbstract=null), Reference(id=1329529195169952402, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=Tang M, Liu Y, Zhang QC, et al. Antitumor efficacy of the Runx2-dendritic cell vaccine in triple-negative breast cancer in vitro[J]. Oncol Lett, 2018, 16(3): 2813-2822., articleTitle=null, refAbstract=null), Reference(id=1329529195245449875, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies[J]. J Clin Invest, 2011, 121(7): 2750-2767., articleTitle=null, refAbstract=null), Reference(id=1329529195316753044, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=Ghallab AM, Eissa RA, El Tayebi HM. CXCR2 small-molecule antagonist combats chemoresistance and enhances immunotherapy in triple-negative breast cancer[J]. Front Pharmacol, 2022, 13: 862125., articleTitle=null, refAbstract=null), Reference(id=1329529195425804949, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=Dent R, André F, Gonçalves A, et al. IMpassion132 double-blind randomised phase Ⅲ trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer[J]. Ann Oncol, 2024, 35(7): 630-642., articleTitle=null, refAbstract=null), Reference(id=1329529195551634070, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=Vinayak S, Tolaney SM, Schwartzberg L, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer[J]. J Am Med Assoc Oncol, 2019, 5(8): 1132-1140., articleTitle=null, refAbstract=null), Reference(id=1329529195652297367, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=Jiang YZ, Liu Y, Xiao Y, et al. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial[J]. Cell Res, 2021, 31(2): 178-186., articleTitle=null, refAbstract=null), Reference(id=1329529195719406232, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=Chen L, Jiang YZ, Wu SY, et al. Famitinib with camrelizumab and nab-paclitaxel for advanced immunomodulatory triple-negative breast cancer (FUTURE-C-Plus): an open-label, single-arm, phase Ⅱ trial[J]. Clin Cancer Res, 2022, 28(13): 2807-2817., articleTitle=null, refAbstract=null), Reference(id=1329529195782320793, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=Fan L, Wang ZH, Ma LX, et al. Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial[J]. Lancet Oncol, 2024, 25(2): 184-197., articleTitle=null, refAbstract=null), Reference(id=1329529195878789786, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics[J]. Lancet Oncol, 2017, 18(3): e143-e152., articleTitle=null, refAbstract=null), Reference(id=1329529197149663899, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=Kus T, Cicin I. A perspective: the integration of ctDNA into response evaluation criteria in solid tumours 1.1 for phase Ⅱ immunotherapy clinical trials[J]. Immunotherapy, 2024, 16(5): 319-329., articleTitle=null, refAbstract=null), Reference(id=1329529197330018972, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=Turner NC, Swift C, Jenkins B, et al. Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer[J]. Ann Oncol, 2023, 34(2): 200-211., articleTitle=null, refAbstract=null), Reference(id=1329529197527151261, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=Soliman H, Hogue D, Han H, et al. Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial[J]. Nat Med, 2023, 29(2): 450-457., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1329529186240279113, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, xref=1., ext=[AuthorCompanyExt(id=1329529186248667722, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, companyId=1329529186240279113, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei Province, China), AuthorCompanyExt(id=1329529186273833547, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, companyId=1329529186240279113, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.武汉大学中南医院甲状腺乳腺外科,湖北 武汉 430071)]), AuthorCompany(id=1329529186332553804, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, xref=2., ext=[AuthorCompanyExt(id=1329529186340942413, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, companyId=1329529186332553804, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Oncology, Urumqi Friendship Hospital, Urumqi 830049, Xinjiang Uygur Autonomous Region, China), AuthorCompanyExt(id=1329529186349331022, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, companyId=1329529186332553804, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.乌鲁木齐市友谊医院肿瘤科,新疆 乌鲁木齐 830049)]), AuthorCompany(id=1329529186416439887, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, xref=3., ext=[AuthorCompanyExt(id=1329529186424828496, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, companyId=1329529186416439887, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Department of General Surgery, People's Hospital of Gannan Tibetan Autonomous Prefecture of Gansu Province, Gannan 747000, Gansu Province, China), AuthorCompanyExt(id=1329529186433217105, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, companyId=1329529186416439887, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.甘肃省甘南藏族自治州人民医院普外一科,甘肃 甘南 747000)]), AuthorCompany(id=1329529186491937362, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, xref=4., ext=[AuthorCompanyExt(id=1329529186500325971, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, companyId=1329529186491937362, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=4.Department of Ultrasound Imaging, Wuhan University Hospital, Wuhan 430071, Hubei Province, China), AuthorCompanyExt(id=1329529186508714580, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, companyId=1329529186491937362, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=4.武汉大学医院超声影像科,湖北 武汉 430071)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2024.08.001, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2024.08.001, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2024.08.001, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2024.08.001, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1723219200000, fullTextJson=null, articleText=null, reference=null)
收藏切换
三阴性乳腺癌免疫治疗的临床应用进展
张亮 1, 2 , 杨彦强 1, 3 , 吴梓芳 4, * , 刘九洋 1, *
世界临床药物 | 医药专论 2024,45(8): 803-808
收起
收藏切换
世界临床药物 |医药专论 2024 , 45 (8) : 803 -808
三阴性乳腺癌免疫治疗的临床应用进展
全屏
[Author(id=1329529186575823446, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329529186651320921, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, authorId=1329529186575823446, language=EN, stringName=Liang ZHANG, firstName=Liang, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei Province, China
2.Department of Oncology, Urumqi Friendship Hospital, Urumqi 830049, Xinjiang Uygur Autonomous Region, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329529186768761434, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, authorId=1329529186575823446, language=CN, stringName=张亮, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 2, address=1.武汉大学中南医院甲状腺乳腺外科,湖北 武汉 430071
2.乌鲁木齐市友谊医院肿瘤科,新疆 乌鲁木齐 830049, bio={"content":"

张亮,副主任医师,研究方向:乳腺癌诊疗与机制研究。

"}, bioImg=null, bioContent=

张亮,副主任医师,研究方向:乳腺癌诊疗与机制研究。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329529186240279113, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, xref=1., ext=[AuthorCompanyExt(id=1329529186248667722, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, companyId=1329529186240279113, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei Province, China), AuthorCompanyExt(id=1329529186273833547, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, companyId=1329529186240279113, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.武汉大学中南医院甲状腺乳腺外科,湖北 武汉 430071)]), AuthorCompany(id=1329529186332553804, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, xref=2., ext=[AuthorCompanyExt(id=1329529186340942413, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, companyId=1329529186332553804, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Oncology, Urumqi Friendship Hospital, Urumqi 830049, Xinjiang Uygur Autonomous Region, China), AuthorCompanyExt(id=1329529186349331022, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, companyId=1329529186332553804, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.乌鲁木齐市友谊医院肿瘤科,新疆 乌鲁木齐 830049)])]), Author(id=1329529186861036124, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329529186965893727, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, authorId=1329529186861036124, language=EN, stringName=Yanqiang YANG, firstName=Yanqiang, middleName=null, lastName=YANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 3, address=1.Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei Province, China
3.Department of General Surgery, People's Hospital of Gannan Tibetan Autonomous Prefecture of Gansu Province, Gannan 747000, Gansu Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329529188605866592, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, authorId=1329529186861036124, language=CN, stringName=杨彦强, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, 3, address=1.武汉大学中南医院甲状腺乳腺外科,湖北 武汉 430071
3.甘肃省甘南藏族自治州人民医院普外一科,甘肃 甘南 747000, bio={"content":"

杨彦强,主治医师,研究方向:乳腺癌诊疗与机制研究。

"}, bioImg=null, bioContent=

杨彦强,主治医师,研究方向:乳腺癌诊疗与机制研究。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329529186240279113, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, xref=1., ext=[AuthorCompanyExt(id=1329529186248667722, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, companyId=1329529186240279113, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei Province, China), AuthorCompanyExt(id=1329529186273833547, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, companyId=1329529186240279113, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.武汉大学中南医院甲状腺乳腺外科,湖北 武汉 430071)]), AuthorCompany(id=1329529186416439887, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, xref=3., ext=[AuthorCompanyExt(id=1329529186424828496, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, companyId=1329529186416439887, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.Department of General Surgery, People's Hospital of Gannan Tibetan Autonomous Prefecture of Gansu Province, Gannan 747000, Gansu Province, China), AuthorCompanyExt(id=1329529186433217105, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, companyId=1329529186416439887, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=3.甘肃省甘南藏族自治州人民医院普外一科,甘肃 甘南 747000)])]), Author(id=1329529188748472930, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329529188861719140, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, authorId=1329529188748472930, language=EN, stringName=Zifang WU, firstName=Zifang, middleName=null, lastName=WU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=4, *, address=4.Department of Ultrasound Imaging, Wuhan University Hospital, Wuhan 430071, Hubei Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329529188962382437, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, authorId=1329529188748472930, language=CN, stringName=吴梓芳, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=4, *, address=4.武汉大学医院超声影像科,湖北 武汉 430071, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329529186491937362, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, xref=4., ext=[AuthorCompanyExt(id=1329529186500325971, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, companyId=1329529186491937362, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=4.Department of Ultrasound Imaging, Wuhan University Hospital, Wuhan 430071, Hubei Province, China), AuthorCompanyExt(id=1329529186508714580, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, companyId=1329529186491937362, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=4.武汉大学医院超声影像科,湖北 武汉 430071)])]), Author(id=1329529189084017255, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329529189289538153, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, authorId=1329529189084017255, language=EN, stringName=Jiuyang LIU, firstName=Jiuyang, middleName=null, lastName=LIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329529189411172970, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, authorId=1329529189084017255, language=CN, stringName=刘九洋, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, *, address=1.武汉大学中南医院甲状腺乳腺外科,湖北 武汉 430071, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329529186240279113, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, xref=1., ext=[AuthorCompanyExt(id=1329529186248667722, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, companyId=1329529186240279113, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei Province, China), AuthorCompanyExt(id=1329529186273833547, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329529185267200582, companyId=1329529186240279113, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.武汉大学中南医院甲状腺乳腺外科,湖北 武汉 430071)])])]
张亮1, 2, 杨彦强1, 3, 吴梓芳4, *, 刘九洋1, *
作者信息
  • 1.武汉大学中南医院甲状腺乳腺外科,湖北 武汉 430071
  • 2.乌鲁木齐市友谊医院肿瘤科,新疆 乌鲁木齐 830049
  • 3.甘肃省甘南藏族自治州人民医院普外一科,甘肃 甘南 747000
  • 4.武汉大学医院超声影像科,湖北 武汉 430071
通讯作者:
吴梓芳,副主任技师,研究方向:超声影像与临床应用。
刘九洋,副主任医师,研究方向:乳腺癌的机制研究。
作者简介:

张亮,副主任医师,研究方向:乳腺癌诊疗与机制研究。

杨彦强,主治医师,研究方向:乳腺癌诊疗与机制研究。

Advances in clinical application of immunotherapy for triple-negative breast cancer
Liang ZHANG1, 2, Yanqiang YANG1, 3, Zifang WU4, *, Jiuyang LIU1, *
Affiliations
  • 1.Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei Province, China
  • 2.Department of Oncology, Urumqi Friendship Hospital, Urumqi 830049, Xinjiang Uygur Autonomous Region, China
  • 3.Department of General Surgery, People's Hospital of Gannan Tibetan Autonomous Prefecture of Gansu Province, Gannan 747000, Gansu Province, China
  • 4.Department of Ultrasound Imaging, Wuhan University Hospital, Wuhan 430071, Hubei Province, China
出版时间: 2024-08-10 doi: 10.13683/j.wph.2024.08.001
文章导航
收藏切换

三阴性乳腺癌(triple-negative breast cancer,TNBC)是一种雌激素受体、孕激素受体和人类表皮生长因子受体2阴性的乳腺癌亚型,其侵袭性及疾病进展速度明显高于其他亚型。目前其主要治疗为手术联合化疗,但晚期TNBC患者的治疗效果不佳。随着对TNBC免疫微环境深入研究,免疫疗法已显示出潜在的治疗价值。TNBC免疫治疗主要包括免疫检查点阻断剂、细胞治疗、肿瘤疫苗以及调整肿瘤微环境。该文对免疫疗法的现状和进展作回顾及总结,有助于TNBC免疫治疗的新认识。

三阴性乳腺癌  /  免疫治疗  /  肿瘤微环境。

Triple-negative breast cancer (TNBC) is a subtype of breast cancer that is negative for estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2, and is significantly more aggressive and progressive than other subtypes. At present, the main treatment is surgery combined chemotherapy, but treatment efficacy of the advanced TNBC patients is poor. With the in-depth study of TNBC immune microenvironment, immunotherapy has shown potential therapeutic value. The immunotherapy of TNBC mainly includes immune checkpoint blockers, cell therapy, tumor vaccines and adjustment of tumor microenvironment. This article reviewed and summarized the current status and progress of immunotherapy, which contributed to the new understanding of TNBC immunotherapy.

triple-negative breast cancer  /  immunotherapy  /  tumor microenvironment
张亮, 杨彦强, 吴梓芳, 刘九洋. 三阴性乳腺癌免疫治疗的临床应用进展. 世界临床药物, 2024 , 45 (8) : 803 -808 . DOI: 10.13683/j.wph.2024.08.001
Liang ZHANG, Yanqiang YANG, Zifang WU, Jiuyang LIU. Advances in clinical application of immunotherapy for triple-negative breast cancer[J]. World Clinical Drug, 2024 , 45 (8) : 803 -808 . DOI: 10.13683/j.wph.2024.08.001

参考文献 引证文献
排序方式:
[1]
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2]
Denkert C, Liedtke C, Tutt A, et al. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies[J]. Lancet, 2017, 389(10087): 2430-2442.
[3]
Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving ratient selection for treatment[J]. Cancer Discov, 2019, 9(2): 176-198.
[4]
Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence[J]. Clin Cancer Res, 2007, 13(15 Pt 1): 4429-4434.
[5]
Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3 771 patients treated with neoadjuvant therapy[J]. Lancet Oncol, 2018, 19(1): 40-50.
[6]
Farshbafnadi M, Pastaki Khoshbin A, Rezaei N. Immune checkpoint inhibitors for triple-negative breast cancer: from immunological mechanisms to clinical evidence[J]. Int Immunopharmacol, 2021, 98: 107876.
[7]
Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase Ⅱ KEYNOTE-086 study[J]. Ann Oncol, 2019, 30(3): 397-404.
[8]
Winer EP, Lipatov O, Im SA, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2021, 22(4): 499-511.
[9]
Schmid P, Lipatov O, Im SA, et al. Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study[J]. Eur J Cancer, 2023, 195: 113393.
[10]
Emens LA, Adams S, Barrios CH, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis[J]. Ann Oncol, 2021, 32(8): 983-993.
[11]
Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial[J]. Lancet, 2020, 396(10265): 1817-1828.
[12]
Wang C, Liu Z, Chen X, et al. Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase Ⅱ trial[J]. Nat Commun, 2023, 14(1): 6654.
[13]
Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial[J]. Lancet, 2020, 396(10257): 1090-1100.
[14]
Park JW, Liu MC, Yee D, et al. Adaptive randomization of neratinib in early breast cancer[J]. N Engl J Med, 2016, 375(1): 11-22.
[15]
Loibl S, Untch M, Burchardi N, et al. A randomised phase Ⅱstudy investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study[J]. Ann Oncol, 2019, 30(8): 1279-1288.
[16]
Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer[J]. N Engl J Med, 2020, 382(9): 810-821.
[17]
Pusztai L, Denkert C, O'Shaughnessy J, et al. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522[J]. Ann Oncol, 2024, 35(5): 429-436.
[18]
中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)乳腺癌诊疗指南: 2023[M]. 北京: 人民卫生出版社, 2023.
[19]
Buchan SL. CTLA-4: checkpoints beyond the membrane[J]. Mol Ther, 2024, 32(2): 279-281.
[20]
Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy[J]. Blood, 2018, 131(1): 58-67.
[21]
Specht J, Lee S, Turtle C, et al. Abstract P2-09-13: A phase I study of adoptive immunotherapy for ROR1+ advanced triple negative breast cancer (TNBC) with defined subsets of autologous T cells expressing a ROR1-specific chimeric antigen receptor (ROR1-CAR)[J]. Cancer Res, 2019, 79(4_Supplement): P2-09-13.
[22]
Yang Y, Vedvyas Y, McCloskey JE, et al. Abstract 2322: ICAM-1 targeting CAR-T cell therapy for triple negative breast cancer[J]. Cancer Res, 2019, 79(13_Supplement): 2322.
[23]
Xia L, Zheng ZZ, Liu JY, et al. EGFR-targeted CAR-T cells are potent and specific in suppressing triple-negative breast cancer both in vitro and in vivo[J]. Clin Transl Immunology, 2020, 9(5): e01135.
[24]
Zhang L, Meng Y, Feng X, et al. CAR-NK cells for cancer immunotherapy: from bench to bedside[J]. Biomark Res, 2022, 10(1): 12.
[25]
Raftery MJ, Franzén AS, Radecke C, et al. Next generation CD44v6-specific CAR-NK cells effective against triple negative breast cancer[J]. Int J Mol Sci, 2023, 24(10): 9038.
[26]
Hu Z. Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer[J]. Sci Rep, 2020, 10(1): 2815.
[27]
Zacharakis N, Huq LM, Seitter SJ, et al. Breast cancers are immunogenic: immunologic analyses and a phase Ⅱ pilot clinical trial using mutation-reactive autologous lymphocytes[J]. J Clin Oncol, 2022, 40(16): 1741-1754.
[28]
Tay C, Tanaka A, Sakaguchi S. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy[J]. Cancer Cell, 2023, 41(3): 450-465.
[29]
Hasegawa K, Ikeda Y, Kunugi Y, et al. Phase Ⅰ study of multiple epitope peptide vaccination in patients with recurrent or persistent cervical cancer[J]. J Immunother, 2018, 41(4): 201-207.
[30]
Takeda K, Kitaura K, Suzuki R, et al. Quantitative T-cell repertoire analysis of peripheral blood mononuclear cells from lung cancer patients following long-term cancer peptide vaccination[J]. Cancer Immunol Immunother, 2018, 67(6): 949-964.
[31]
Butterfield LH, Zhao F, Lee S, et al. Immune correlates of GM-CSF and melanoma peptide vaccination in a randomized trial for the adjuvant therapy of resected high-risk melanoma (E4697)[J]. Clin Cancer Res, 2017, 23(17): 5034-5043.
[32]
Tang M, Liu Y, Zhang QC, et al. Antitumor efficacy of the Runx2-dendritic cell vaccine in triple-negative breast cancer in vitro[J]. Oncol Lett, 2018, 16(3): 2813-2822.
[33]
Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies[J]. J Clin Invest, 2011, 121(7): 2750-2767.
[34]
Ghallab AM, Eissa RA, El Tayebi HM. CXCR2 small-molecule antagonist combats chemoresistance and enhances immunotherapy in triple-negative breast cancer[J]. Front Pharmacol, 2022, 13: 862125.
[35]
Dent R, André F, Gonçalves A, et al. IMpassion132 double-blind randomised phase Ⅲ trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer[J]. Ann Oncol, 2024, 35(7): 630-642.
[36]
Vinayak S, Tolaney SM, Schwartzberg L, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer[J]. J Am Med Assoc Oncol, 2019, 5(8): 1132-1140.
[37]
Jiang YZ, Liu Y, Xiao Y, et al. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial[J]. Cell Res, 2021, 31(2): 178-186.
[38]
Chen L, Jiang YZ, Wu SY, et al. Famitinib with camrelizumab and nab-paclitaxel for advanced immunomodulatory triple-negative breast cancer (FUTURE-C-Plus): an open-label, single-arm, phase Ⅱ trial[J]. Clin Cancer Res, 2022, 28(13): 2807-2817.
[39]
Fan L, Wang ZH, Ma LX, et al. Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial[J]. Lancet Oncol, 2024, 25(2): 184-197.
[40]
Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics[J]. Lancet Oncol, 2017, 18(3): e143-e152.
[41]
Kus T, Cicin I. A perspective: the integration of ctDNA into response evaluation criteria in solid tumours 1.1 for phase Ⅱ immunotherapy clinical trials[J]. Immunotherapy, 2024, 16(5): 319-329.
[42]
Turner NC, Swift C, Jenkins B, et al. Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer[J]. Ann Oncol, 2023, 34(2): 200-211.
[43]
Soliman H, Hogue D, Han H, et al. Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial[J]. Nat Med, 2023, 29(2): 450-457.
2024年第45卷第8期
19
7
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2024.08.001
  • 接收时间:2024-05-29
  • 首发时间:2026-11-17
  • 出版时间:2024-08-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2024-05-29
基金
作者信息
    1.武汉大学中南医院甲状腺乳腺外科,湖北 武汉 430071
    2.乌鲁木齐市友谊医院肿瘤科,新疆 乌鲁木齐 830049
    3.甘肃省甘南藏族自治州人民医院普外一科,甘肃 甘南 747000
    4.武汉大学医院超声影像科,湖北 武汉 430071

通讯作者:

吴梓芳,副主任技师,研究方向:超声影像与临床应用。
刘九洋,副主任医师,研究方向:乳腺癌的机制研究。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2024.08.001
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏